Paper20007699
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Yuan H and 7 others. J Biol Chem, 2010. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. Papers, record 20007699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20007699
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Fusion Proteins, bcr-abl | Major topic |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Major topic |
| Antineoplastic Agents | |
| Apoptosis | |
| Benzamides | |
| Blotting, Western | |
| Cell Cycle | |
| Cell Line | |
| Cell Proliferation | |
| Humans | |
| Imatinib Mesylate | |
| Immunoprecipitation | |
| In Situ Hybridization, Fluorescence | |
| Mutation | |
| Piperazines | |
| Pyrimidines | |
| RNA, Small Interfering | |
| Reactive Oxygen Species |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6321612 | Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. | Int J Cell Cloning | 1983 | https://conductscience.org/library/papers/6321612 | PubMed |
| 2 | 9345054 | The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. | Blood | 1997 | https://conductscience.org/library/papers/9345054 | PubMed |
| 3 | 16527898 | BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. | Blood | 2006 | https://conductscience.org/library/papers/16527898 | PubMed |
| 4 | 15459011 | A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. | Blood | 2005 | https://conductscience.org/library/papers/15459011 | PubMed |
| 5 | 17303698 | Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. | Blood | 2007 | https://conductscience.org/library/papers/17303698 | PubMed |
| 6 | 17470736 | Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. | J Natl Cancer Inst | 2007 | https://conductscience.org/library/papers/17470736 | PubMed |
| 7 | 12730117 | Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. | Blood | 2003 | https://conductscience.org/library/papers/12730117 | PubMed |
| 8 | 12869662 | Specific targeted therapy of chronic myelogenous leukemia with imatinib. | Pharmacol Rev | 2003 | https://conductscience.org/library/papers/12869662 | PubMed |
| 9 | 11780146 | Structure of the Bcr-Abl oncoprotein oligomerization domain. | Nat Struct Biol | 2002 | https://conductscience.org/library/papers/11780146 | PubMed |
| 10 | 17189410 | Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17189410 | PubMed |
| 11 | 12887890 | Autoinhibition of Bcr-Abl through its SH3 domain. | Mol Cell | 2003 | https://conductscience.org/library/papers/12887890 | PubMed |
| 12 | 15705718 | Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15705718 | PubMed |
| 13 | 8246975 | A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. | Mol Cell Biol | 1993 | https://conductscience.org/library/papers/8246975 | PubMed |
| 14 | 11423618 | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. | Science | 2001 | https://conductscience.org/library/papers/11423618 | PubMed |
| 15 | 12499247 | Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). | Cancer Res | 2002 | https://conductscience.org/library/papers/12499247 | PubMed |
| 16 | 9808572 | Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. | Blood | 1998 | https://conductscience.org/library/papers/9808572 | PubMed |
| 17 | 15289338 | Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. | Cancer Res | 2004 | https://conductscience.org/library/papers/15289338 | PubMed |
| 18 | 15256671 | Overriding imatinib resistance with a novel ABL kinase inhibitor. | Science | 2004 | https://conductscience.org/library/papers/15256671 | PubMed |
| 19 | 14758366 | Rational siRNA design for RNA interference. | Nat Biotechnol | 2004 | https://conductscience.org/library/papers/14758366 | PubMed |
| 20 | 17522713 | Chronic myeloid leukaemia as a model of disease evolution in human cancer. | Nat Rev Cancer | 2007 | https://conductscience.org/library/papers/17522713 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36453102 | Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition. | Haematologica | 2023 | https://conductscience.org/library/papers/36453102 | PubMed |
| 36379918 | BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. | Cell Death Discov | 2022 | https://conductscience.org/library/papers/36379918 | PubMed |
| 35524023 | Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. | Int J Hematol | 2022 | https://conductscience.org/library/papers/35524023 | PubMed |
| 35338182 | Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model. | Sci Rep | 2022 | https://conductscience.org/library/papers/35338182 | PubMed |
| 34873458 | Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/34873458 | PubMed |
| 34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/34659899 | PubMed |
| 34616685 | Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining. | Front Oncol | 2021 | https://conductscience.org/library/papers/34616685 | PubMed |
| 33918810 | GSK-3α Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKp30-Dependent Manner. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33918810 | PubMed |
| 33334308 | Inferring time-dependent population growth rates in cell cultures undergoing adaptation. | BMC Bioinformatics | 2020 | https://conductscience.org/library/papers/33334308 | PubMed |
| 32708713 | PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32708713 | PubMed |
| 31761618 | CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. | EBioMedicine | 2019 | https://conductscience.org/library/papers/31761618 | PubMed |
| 30787317 | Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. | Sci Rep | 2019 | https://conductscience.org/library/papers/30787317 | PubMed |
| 30711891 | A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. | Leuk Res | 2019 | https://conductscience.org/library/papers/30711891 | PubMed |
| 30049824 | BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. | Haematologica | 2018 | https://conductscience.org/library/papers/30049824 | PubMed |
| 29967475 | T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. | Sci Rep | 2018 | https://conductscience.org/library/papers/29967475 | PubMed |
| 29608815 | Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase. | ChemMedChem | 2018 | https://conductscience.org/library/papers/29608815 | PubMed |
| 29116012 | Connexin 32 and connexin 43 are involved in lineage restriction of hepatic progenitor cells to hepatocytes. | Stem Cell Res Ther | 2017 | https://conductscience.org/library/papers/29116012 | PubMed |
| 28819281 | Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. | Leukemia | 2017 | https://conductscience.org/library/papers/28819281 | PubMed |
| 27726390 | Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. | J Nat Prod | 2016 | https://conductscience.org/library/papers/27726390 | PubMed |
| 27581146 | A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations. | Methods Mol Biol | 2016 | https://conductscience.org/library/papers/27581146 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| BCR | 613 | PubTator's text mining | https://conductscience.org/library/genes/613 | NCBI Gene |
| HPRT1 | 3251 | PubTator's text mining | https://conductscience.org/library/genes/3251 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20007699
GET https://conductscience.org/api/papers/v1/20007699/references?page=2